Drug Trial Radar · NCT07306832
A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Last checked: Nov 20, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
18
Planned (sponsor's estimate)
Start
May 20, 2026
Primary completion
Apr 2028
Study completion Mar 2030
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Dec 29, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 6 months, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Acute myeloid leukemia (AML) is an aggressive blood cancer, withwith few options for participants who relapse after treatment or who don't respond to treatment. This study will assess the adverse events and how pivekimab sunirine moves through the body in pediatric participants with relapsed or refractory (R/R) AML. Pivekimab sunirine is a drug being evaluated in the treatment of AML. This is an open label, single arm study, participants will be enrolled in 1 of the 3 cohorts based on their age and will receive pivekimab sunirine at a dose based on their weight. Around 18 pediatric participants with a diagnosis of AML will be enrolled in the study at approximately 30 sites around the world. Participants will receive intravenous (IV) pivekimab sunirine alone. The total study duration is approximately 28 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, and checking for side effects.
Conditions
- Acute Myeloid Leukemia
Interventions
Pivekimab SunirineDrug
Intravenous
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Treatment-Emergent Adverse Events (TEAEs) Leading to Treatment DiscontinuationTime frame: Up to Approximately 24 Months
- Maximum Observed Serum/Plasma Concentration (Cmax) of Intact Antibody-Drug Conjugate (ADC)Time frame: Up to Approximately 22 Months
- Cmax of FGN849 PayloadTime frame: Up to Approximately 22 Months
- Area Under the Concentration-Time Curve (AUC) of Intact ADCTime frame: Up to Approximately 22 Months
- AUC of FGN849 payloadTime frame: Up to Approximately 22 Months
- Time to Cmax (Tmax) of Intact ADCTime frame: Up to Approximately 22 Months
- Tmax of FGN849 PayloadTime frame: Up to Approximately 22 Months
Locations
14 sites in 7 countries. Site status is shown where the registry gives one.
Lucile Packard Children's Hospital /ID# 276015
Palo Alto, California · Recruiting
Children'S Healthcare Of Atlanta - Arthur M. Blank Hospital /ID# 275740
Atlanta, Georgia · Recruiting
New York Medical College /ID# 275597
Valhalla, New York · Recruiting
Tristar Centennial Medical Center /ID# 275831
Nashville, Tennessee · Recruiting
Children's Medical Center Dallas /ID# 275930
Dallas, Texas · Recruiting
The Children's Hospital at Westmead /ID# 275672
Westmead, New South Wales, Australia · Recruiting
Perth Children'S Hospital /ID# 275673
Perth, Western Australia, Australia · Recruiting
Hopital Armand Trousseau /ID# 276231
Paris, France · Recruiting
Chu Bordeaux - Hopital Pellegrin /ID# 277645
Bordeaux, New Aquitaine, France · Recruiting
Ospedale Pediatrico Bambino Gesu /ID# 275692
Rome, Roma, Italy · Recruiting
Seoul National University Hospital /ID# 276978
Seoul, Seoul Teugbyeolsi, South Korea · Recruiting
Samsung Medical Center /ID# 276979
Seoul, Seoul Teugbyeolsi, South Korea · Recruiting
National Taiwan University Hospital /ID# 276635
Taipei, Taiwan · Recruiting
Cambridge University Hospital /ID# 277041
Cambridge, Cambridgeshire, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.